Dolutegravir intensification for prevention of perinatal transmission in a vertically infected pregnant women harboring multidrug-resistant HIV-1
Abstract
Dolutegravir (DTG) is a second generation integrase inhibitor witch retains susceptibility against raltegravir and elvitegravir resistant strains. However, it´s not recommended for use in pregnancy unless benefits outweigh potential risks and literature of exposure to this drug in pregnancy is extremely limited. In this report, we present the case of a perinatally infected woman harboring multidrug-resistant HIV whose antiretroviral treatment was successfully intensified with DTG in third trimester due to detectable viremia in the context of an obstetric emergency.
Keywords
Full Text:
PDFReferences
Cruz ML, Cardoso CA, João EC, Gomes IM, Abreu TF, Oliveira RH. Pregnancy in HIV vertically infected adolescents and young women: new generation of HIV-exposed infants. AIDS 2010; 24:2727–2731.
Calitri C, Gabiano C, Galli L, Chiappini E, Giaquinto C, Buffolano W, et al. The second generation of HIV-1 vertically exposed infants: a case series from the Italian Register for paediatric HIV infection. BMC Infectious Diseases 2014; 14:277.
British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). HIV Medicine; 2014; 15(Suppl. 4):1–77.
European AIDS Clinical Society (EACS). Guidelines Version 8.0 2015. http://www.eacsociety.org/files/2015_eacsguidelines_8_0-english_rev-20160124.pdf. [Accessed 15 April 2016]
Nóbrega I, Travassos AG, Haguihara T, Amorim F, Brites C. Use of raltegravir in late-presenting HIV-infected pregnant women. AIDS Res Hum Retroviruses 2013; 29:1451-1454.
Rahangdale L, Cates J, Potter J, Badell ML, Seidman D, Miller ES, et al. Integrase inhibitors in late pregnancy and rapid HIV viral load reduction. Am J Obstet Gynecol 2016; 214:385.e1-7.
Tivicay (dolutegravir) tablets, for oral use. https://www.viivhealthcare.com/media/58599/us_tivicay.pdf. [Accessed 15 April 2016]
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. http://aidsinfo.nih.gov/guidelines. [Accessed 16 April 2016]
Stanford University. HIV Drug Resistance Database. http://sierra2.stanford.edu/sierra/servlet/JSierra. [Accessed 15 April 2016]
Pain JB, Lê MP, Caseris M, Amiel C, Lassel L, Charpentier, C, et al. Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy. Antimicrob Agents Chemother 2015; 59:3660-3662.
DOI: http://dx.doi.org/10.18103/imr.v0i4.80
Refbacks
- There are currently no refbacks.